Editorial intelligence

Peptide Unfiltered

Clear-eyed reviews of the claims, failures, regulatory signals and product-quality risks the marketing leaves out.

Featured investigation

Evidence is not a vibe.

Our framework separates the question people want answered from the question a study actually tested—then keeps approval, safety and product quality in their own lanes.

Read the evidence field guide
01
Evidence vs. hype · 11 min read

BPC-157: the gap between recovery lore and human evidence

Animal models, anecdotes and a compelling mechanism can create a strong story. They still do not establish human efficacy, a validated protocol or product quality.

Analysis preview →
02
Product quality · 8 min read

The bad-vial problem is bigger than purity

A single HPLC percentage cannot establish identity, net content, sterility, endotoxin control, custody or formulation stability.

Analysis preview →
03
Regulatory action · 7 min read

What an FDA compounding review does—and does not—mean

Regulatory categories, bulk-substance reviews and product approval are different questions. Blurring them creates false reassurance.

Analysis preview →
04
Clinical postmortem · 9 min read

Promising mechanism, failed program

Why target engagement, a phase 2 signal and an impressive chart can still collapse under larger trials, safety or an endpoint mismatch.

Analysis preview →
05
Marketing claims · 6 min read

When a blend borrows credibility

A named stack is a new intervention. It cannot inherit the strongest study, safest component or approval status inside the vial.

Analysis preview →
06
Community claims · 5 min read

Anecdote is a signal—not a denominator

Community reports can surface questions. Without verification, controls and a denominator, they cannot quantify benefit or risk.

Analysis preview →